Compare HOG & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOG | ICUI |
|---|---|---|
| Founded | 1903 | 1984 |
| Country | United States | United States |
| Employees | 6400 | N/A |
| Industry | Motor Vehicles | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 3.0B |
| IPO Year | 1994 | 1995 |
| Metric | HOG | ICUI |
|---|---|---|
| Price | $25.41 | $122.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $24.00 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 3.1M | 239.3K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | 0.22 | ★ 1.20 |
| Revenue | ★ $4,473,175,000.00 | $2,231,262,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.79 | $4.46 |
| P/E Ratio | $116.09 | ★ $101.70 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.09 | $107.02 |
| 52 Week High | $31.25 | $160.29 |
| Indicator | HOG | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 63.96 | 46.36 |
| Support Level | $24.34 | $121.52 |
| Resistance Level | $28.74 | $133.16 |
| Average True Range (ATR) | 1.11 | 4.74 |
| MACD | 0.05 | 0.64 |
| Stochastic Oscillator | 67.71 | 44.88 |
Harley-Davidson is a leading global manufacturer of heavyweight motorcycles across the custom, cruising, and touring categories, as well as related merchandise, parts, and accessories. In recent years, the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand. Its captive finance arm, Harley-Davidson Financial Services, provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley captured around 34% of the heavyweight domestic market in 2025.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.